PRTA
Prothena Corporation plc
stockNASDAQ
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson's disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena's elite team has a recognized track record both f
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 7.97 | 2026-11-06 | +2.51% | 4.913 |
| 1M | 8.36 | 2026-10-13 | -2.27% | 1.861 |
| 3M | 9.08 | 2026-08-13 | -10.02% | 1.502 |
| 6M | 9.60 | 2026-05-13 | -14.90% | 1.004 |
| 1Y | 10.18 | 2025-11-13 | -19.75% | 1.054 |
| 2Y | 17.23 | 2024-11-13 | -52.58% | — |
| 5Y | 57.19 | 2021-11-12 | -85.71% | 1.388 |
Prothena Corporation plc (NASDAQ:PRTA) stock price today is $8.17, and today's volume is 280,813. PRTA is down 0.729% today. The 30 day average volume is 518,866. PRTA market cap is $419.53M with 51.35M shares outstanding.